| Jun'18 | Jun'17 | Jun'16 | ||||
|---|---|---|---|---|---|---|
Revenue | ||||||
17,341 | 2,412 | 42,548 | ||||
Research & development | ||||||
65,927 | 58,914 | 50,013 | ||||
Manufacturing commercialization | ||||||
5,508 | 12,065 | 29,763 | ||||
Management and administration | ||||||
21,907 | 23,007 | 22,500 | ||||
Fair value remeasurement of contingent consideration | ||||||
-10,541 | 130 | -28,112 | ||||
Other operating income and expenses | ||||||
1,312 | 1,489 | 2,714 | ||||
Finance costs | ||||||
1,829 | - | - | ||||
Impairment of intangible assets | ||||||
- | - | 61,919 | ||||
Loss before income tax | ||||||
-65,977 | -90,215 | -90,821 | ||||
Income tax benefit/(expense) | ||||||
-30,687 | -13,400 | -86,694 | ||||
Loss attributable to the owners of Mesoblast Limited | ||||||
-35,290 | -76,815 | -4,127 | ||||
Losses per share from continuing operations attributable to the ordinary equity holders of the Group: | ||||||
Basic - losses per share | ||||||
-0.07 | -0.19 | -0.01 | ||||
Diluted - losses per share | ||||||
-0.07 | -0.19 | -0.01 | ||||